Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.3152W HIGH $55.60
Volume
20.95 K
Value Traded
131.29 K
Short % Float
7.06%
-18.09%Week
-27.36%1 Month
-72.3%3 Month
-85.34%6 Month
-99.61%5 Year
-99.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.15 M
EPS (TTM)
-34.02
P/E Ratio
-
Ent. Value
-7.60 M
Total Shares
957.63 K
Float Shares
840.00 K
Insiders
14.77%
Institutions
6.99%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
XAIR Catalyst Timeline
Dated clinical, regulatory and corporate events for Beyond Air, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Beyond Air, Inc.
403Total events
10Upcoming
89Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Quarterly UpdateCorporate
Fiscal Year End 2026 Financial Results Conference Call and Webcast
▲Partnership / LicenseCorporate
Awarded national group purchasing agreement with leading U.S. GPO
hypoxic respiratory failuresource ↗
▼Reverse Stock SplitCorporate
Board approved 1-for-20 reverse stock split to regain Nasdaq compliance
◆Oral PresentationPresentation
Beyond Air to participate in D. Boral Capital Global Conference 2026
◆Poster PresentationUNOPresentation
Poster presentation of Phase 1 data on intratumoral UNO at AACR Annual Meeting 2026
solid tumor metastasessource ↗
▲Product LaunchPost-Market
National group purchasing agreement awarded with a top 3 U.S. GPO for LungFit PH
hypoxic respiratory failure in term and near-term neonatessource ↗
◆Oral PresentationUNOPresentation
Phase 1a data from UNO program to be presented at AACR 2026
solid tumorssource ↗
◆AbstractUNOPresentation
Abstract featuring Phase 1 data on intratumoral UNO in solid tumor metastases to be presented at AACR 2026
solid tumor metastasessource ↗
▲PublicationPresentation
Publication of independent review article on high-dose inhaled nitric oxide for antimicrobial effects
respiratory infectionssource ↗
▲Partnership / LicenseCorporate
XTL acquires 85% of NeuroNOS from Beyond Air
Autism Spectrum Disordersource ↗
◆Trial InitiationLungFitTrial
Plan to initiate US trial for NTM in calendar year 2025
nontuberculous mycobacteria (NTM)source ↗
◆Trial InitiationTrial
Plan to initiate first-in-human study for ASD in 2025
autism spectrum disorder (ASD)source ↗
▲Partnership / LicenseCorporate
Signed international distribution agreements for LungFit PH in Germany, Brazil, Austria, Netherlands, Sri Lanka
hypoxic respiratory failure in term and near-term neonatessource ↗
◆Other Regulator MilestoneEx-US Regulatory
Expected regulatory approvals in eight countries under Getz Healthcare partnership by calendar year-end
pulmonary hypertension of the newborn (PPHN) and cardiac surgerysource ↗
◆Topline ReadoutUNOClinical Data
Topline data from Phase 1b portion anticipated late 2025 or early 2026
advanced solid tumors (cutaneous and subcutaneous)source ↗
◆Quarterly UpdateCorporate
Second fiscal quarter 2026 financial results conference call and webcast
▼Debt Royalty FinancingCorporate
Closed $12M debt financing and up to $20M equity line with Streeterville Capital
▲Manufacturing MilestoneCMC / Inspection
Achieved Medical Device Single Audit Program (MDSAP) certificate
▲Patent GrantedIP / Competition
USPTO granted patent allowance for second-generation LungFit PH design patent through 2040
hypoxic respiratory failure in neonatessource ↗
▲Other Regulator MilestoneEx-US Regulatory
Achieved MDSAP certification for quality management system
▲Orphan Drug DesignationBA-101Designation
FDA granted Orphan Drug Designation to BA-101 for GBM
Glioblastomasource ↗
▲Orphan Drug DesignationBA-102Designation
FDA granted Orphan Drug Designation to BA-102 for PMS
Phelan-McDermid Syndromesource ↗
▼Equity OfferingCorporate
Secured up to $32 million capital through promissory note and equity line of credit with Streeterville Capital
◆Oral PresentationPresentation
Beyond Air to participate in ROTH 4th Annual Healthcare Opportunities Conference
▲Orphan Drug DesignationBA-101Designation
FDA granted Orphan Drug Designation to BA-101 for glioblastoma
Glioblastoma (GBM)source ↗
◆Oral PresentationPresentation
Beyond Air to present at H.C. Wainwright 27th Annual Global Investment Conference
▲Partnership / LicenseCorporate
Signed new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador
hypoxic respiratory failure in neonatessource ↗
▲Partnership / LicenseCorporate
National group purchasing agreement with Premier, Inc. for LungFit PH
hypoxic respiratory failure in neonatessource ↗
●Trial CompletionUNOTrial
Phase 1a monotherapy Part A completed for UNO in solid tumors
advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How XAIR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-19 | UNO (ultra-high concentration nitric oxide) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F14 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
4
Drugs Scored
-
rNPV / MCap
Top 99%
Micro Cap(rank 651 of 658)
Percentile Rank
Beyond Air, Inc. has significant pipeline risk (14/100), with 4 assets in development, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every XAIR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LungFit GO Breakthrough | NTM Lung Infection | 2022-10-17 | total subjects: 15; mean age: 62.1; female percentage: 75; titration dose: 250 ppm; inhalations administered: 2492; treatment compliance: >90%; serious adverse events: 0; culture conversion: 1Read More | Beyond Air Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit GO at the CHEST Annual Meeting 2022 - Data show favorable safety, tolerabilitRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lin Yi-Chien10% Owner | Buy | 15,393 145,393 held | $2.80 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XAIR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0 % | 2.10 M | 1.20 M |
XAIR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XAIR ranks across every disease it competes in
Competitive Position is a premium feature
See how XAIR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXAIR News
XAIR▼ -9.1%on this news
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air, Inc. has announced preliminary revenue of $2.3 million for Q3 2026, marking a 30% increase from the previous quarter and a 27% increase year-over-year. This growth reflects the successful adoption of their LungFit PH system. The company reaffirms its revenue guidance of $8 million for 2026 and $16-$18 million for 2027, pending FDA approval of their second-generation system.
Read more →XAIRBeyond Air to Participate in the 2026 Cantor Global Healthcare Conference
Beyond Air, Inc. will participate in the 2026 Cantor Global Healthcare Conference from September 9-11, 2026. The management team will host a fireside chat on September 10 at 3:55 PM EDT, which will be available via a live webcast. The company focuses on nitric oxide therapies for respiratory and neurological conditions.
Read more →XAIR▼ -11.4%on this newsshared move
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Beyond Air, Inc. has received FDA Breakthrough Device Designation for its LungFit GO device, aimed at treating nontuberculous mycobacterial pulmonary disease (NTM-PD). This designation highlights the unmet medical need for effective treatments in this area. Clinical trials indicate that patients can safely self-administer inhaled nitric oxide at home, showing promising results in improving quality of life and reducing mycobacterial burden.
Read more →XAIRBeyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air has entered a definitive agreement to sell its stake in NeuroNOS to UNIVO Pharmaceutical Industries. In exchange, Beyond Air will receive shares representing 19.99% of UNIVO's capital and could earn up to $32.5 million in milestone payments. This transaction aims to provide NeuroNOS with the resources needed to advance its pipeline for neurological disorders.
Read more →XAIR▲ +14.4%on this news
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Beyond Air reported financial results for Q2 2026, achieving $1.8 million in revenue. The company reaffirmed its revenue guidance of $8 million for 2026 and $16-$18 million for 2027. A PMA supplement for the second-generation LungFit PH system is currently under FDA review, with approval anticipated in the second half of 2026. Additionally, Beyond Air secured financing of up to $30.1 million to support its expansion efforts.
Read more →XAIRBeyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
Beyond Air, Inc. will report its financial results for the quarter ending June 30, 2026, on August 13, 2026. The company's management will host a conference call and webcast at 8:00 a.m. ET to discuss these results. Beyond Air focuses on using nitric oxide to treat various medical conditions and has received FDA approval for its LungFit PH system.
Read more →XAIRBeyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Beyond Air, Inc. has announced a private placement offering expected to raise up to $30.1 million. The funds will be used for the commercial launch of its LungFit PH device, pending regulatory approval. The offering includes common stock and warrants, with participation from institutional investors and company executives. The closing is anticipated around July 31, 2026.
Read more →XAIRBeyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Beyond Air, Inc. reported a 107% increase in revenue for fiscal year 2026, reaching $7.7 million. The company announced positive revenue guidance for 2026 and 2027, anticipating significant growth driven by the second-generation LungFit PH system, currently under FDA review. Despite a net loss of $33.2 million, the company is optimistic about its future market opportunities.
Read more →XAIR▲ +14.4%on this newsshared move
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
Beyond Air, Inc. has announced a conference call to discuss its fiscal year-end financial results for 2026. The call is scheduled for June 26, 2026, at 8:00 am ET. The company specializes in medical devices and biopharmaceuticals, particularly utilizing nitric oxide for treating respiratory and neurological conditions. They have received FDA approval for their LungFit PH system.
Read more →XAIRBeyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Beyond Air, Inc. is urging stockholders to vote 'FOR' all proposals at the upcoming Special Meeting scheduled for June 18, 2026. The Board of Directors recommends this action to address a potential delisting from Nasdaq due to the company's stock price falling below the required minimum. A reverse stock split is proposed to increase the stock price above $1.00, which is critical for maintaining access to capital markets and investor eligibility.
Read more →XAIR▲ +5.7%on this news
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
Beyond Air, Inc. has received approval from the Nasdaq Hearings Panel to continue its listing, contingent upon regaining compliance with the Bid Price Rule by July 31, 2026. The company is currently compliant with other listing requirements. A special meeting for shareholders to vote on a proposed reverse stock split is scheduled for June 18, 2026. CEO Robert Goodman expressed confidence in the company's compliance plan and ongoing commercial initiatives.
Read more →XAIR▼ -11.6%on this news· ran to -22% by day 1
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
Beyond Air, Inc. announced its participation in the D. Boral Capital Global Conference 2026, scheduled for May 7th at The Plaza Hotel in New York. CEO Robert Goodman and CFO Dan Moorhead will represent the company. Beyond Air focuses on using nitric oxide to treat respiratory illnesses and has received FDA approval for its LungFit PH system.
Read more →XAIRBeyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
Beyond Air, Inc. has secured a national group purchasing agreement for its LungFit PH system, effective April 1, 2026. This agreement enhances access for nearly 2,000 hospitals and health systems in the U.S. The partnership with leading GPOs aims to streamline the adoption of the tankless nitric oxide solution, supporting efficient healthcare delivery.
Read more →XAIR▼ -6.7%on this news
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
Beyond Air, Inc. announced the resignation of CEO Steve Lisi and the appointment of Robert Goodman as the new CEO. Lisi, who led the company for nine years, is stepping down to pursue other opportunities. Goodman, previously the Chief Commercial Officer, is expected to enhance the company's commercial execution and expand market adoption of their LungFit PH technology.
Read more →XAIR▼ -7.3%on this news
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
Beyond Air, Inc. commented on a new independent review highlighting the antimicrobial effects of high-dose inhaled nitric oxide (iNO). The article presents evidence that high-dose iNO may serve as a broad-spectrum therapy for respiratory infections. It reviews data from 27 studies and suggests future research opportunities in various pulmonary conditions.
Read more →XAIRBeyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Beyond Air, Inc. reported a 105% increase in revenue for fiscal Q3 2026, reaching $2.2 million. The company maintains its revenue guidance of $8-10 million for the fiscal year. A binding letter of intent was signed for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS, potentially providing up to $32.5 million. Additionally, Phase 1a data from the UNO program will be presented at the AACR Annual Meeting in April 2026.
Read more →XAIRBeyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
Beyond Cancer, Ltd. has been selected to present Phase 1 trial data on intratumoral ultra-high concentration nitric oxide (UNO) at the AACR Annual Meeting 2026. This presentation highlights the potential of UNO as an immunotherapeutic for solid tumors. The event will take place from April 17-22, 2026, in San Diego, California.
Read more →XAIR▼ -14.2%on this news
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Beyond Air, Inc. has announced a private placement of $5 million, issuing nearly 3.93 million shares of common stock and associated warrants. The placement is priced at $1.272 per share, with expected gross proceeds to be used for working capital and corporate purposes. The closing is anticipated around January 16, 2026, pending customary conditions.
Read more →XAIR▼ -14.2%on this newsshared move
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has announced the acquisition of 85% of NeuroNOS, a company focused on developing disease-modifying therapies for Autism Spectrum Disorder. This acquisition is significant as it addresses a critical unmet need, with no FDA-approved therapies currently available. NeuroNOS is led by a team that includes two Nobel Laureates, enhancing its scientific foundation. The acquisition also comes with FDA Orphan Drug designations for related conditions, promising a strong market position.
Read more →About Beyond Air, Inc.
Headquarters900 STEWART AVENUE, GARDEN CITY, NY, 11530
BIOPHARMAWATCH ELITE PLUS
Trade the next XAIR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime